Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Pharvaris (NASDAQ:PHVS) in a research note published on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

Other equities analysts have also issued reports about the company. Wedbush restated an “outperform” rating and set a $27.00 target price on shares of Pharvaris in a research report on Thursday, June 5th. Cantor Fitzgerald cut their price objective on Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $36.20.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $17.05 on Wednesday. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The firm has a market cap of $891.54 million, a PE ratio of -6.09 and a beta of -2.86. The business has a fifty day moving average of $15.75 and a 200-day moving average of $17.00.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). On average, analysts anticipate that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG lifted its position in shares of Pharvaris by 55.1% during the 1st quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock worth $442,000 after buying an additional 10,006 shares during the last quarter. TD Asset Management Inc raised its position in Pharvaris by 41.5% in the first quarter. TD Asset Management Inc now owns 78,122 shares of the company’s stock valued at $1,227,000 after purchasing an additional 22,906 shares during the last quarter. Palumbo Wealth Management LLC raised its position in Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company’s stock valued at $221,000 after purchasing an additional 3,881 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pharvaris by 30.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock valued at $1,222,000 after purchasing an additional 14,838 shares during the last quarter. Finally, Woodline Partners LP bought a new position in Pharvaris in the fourth quarter valued at about $853,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.